AFP and hepatocellular carcinoma: Though a few recent studies [48], [49] proposed that preoperative AFP levels are not useful for predicting postoperative survival of patients with early-stage HCC, AFP is used as a biomarker of HCC diagnosis [50] and has even proven useful as a marker for predicting antitumor response after radiofrequency ablation [51] and sorafenib therapy [52].